Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 26, 2024
Reporting Period: Event-based report regarding clinical trial progress.
The Company is a Delaware corporation focused on the development of Ropidoxuridine for the treatment of glioblastoma. This filing serves as a Regulation FD disclosure announcing a significant milestone in its Phase 2 clinical trial.
Key Financial Metrics
This Form 8-K is an event-driven report and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Clinical Progress
The primary material event reported is the enrollment and dosing of the first patient at the UVA Cancer Center in the Company's Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma.
- Previous Milestone: Patient dosing was previously announced at Miami Cancer Institute (Baptist Health South).
- Trial Scope: UVA Cancer Center is one of six centers conducting the trial.
- Target Population: IDH wild-type, methylation negative glioblastoma patients (aggressive brain tumors with radiation as the current standard of care).
- Survival Context: More than half of patients in this cohort survive less than 12 months after diagnosis.
Guidance, Outlook, and Trial Design
Management outlined the specific design and future steps for the Phase 2 trial:
- Initial Cohort: 40 patients randomized into two dose groups (20 patients at 1,200 mg/day and 20 patients at 960 mg/day) to determine the optimal dose.
- Expansion Phase: Upon determining the optimal dose, an additional 14 patients will be added to the trial at that dose.
- Statistical Goal: The expansion aims to achieve statistical significance with the primary endpoint being survival compared to historical controls.
Risks and Forward-Looking Statements: The filing includes standard disclaimers that forward-looking statements are subject to risks and uncertainties. Actual results may differ materially from expectations. The Company undertakes no obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the press release (Exhibit 99.1) for detailed trial protocols and safety data.
- Confirm the enrollment status at the remaining five cancer centers participating in the trial.
- Monitor future filings for the determination of the optimal dose and the initiation of the expansion phase.
- Review the Company's most recent 10-K or 10-Q for current cash runway and liquidity status, as this 8-K does not provide financial data.